[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Quinine.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Quinine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Quinine.]
[B01AD01, streptokinase, The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinine.]
[J01GA01, streptomycin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Streptomycin.]
[M03AB01, succinylcholine, The therapeutic efficacy of Succinylcholine can be increased when used in combination with Quinine.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Quinine.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Quinine is combined with Sulfamethoxazole.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Quinine can be decreased when combined with Sulfinpyrazone.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Quinine can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Quinine.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Quinine.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Quinine is combined with Sulthiame.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Quinine is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Glymidine.]
[L01BB02, mercaptopurine, The serum concentration of Mercaptopurine can be increased when it is combined with Quinine.]
[N06DA01, tacrine, The metabolism of Quinine can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Quinine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Quinine.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Quinine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Quinine.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Quinine.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Quinine.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Quinine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Tetracaine.]
[S03AA02, tetracycline, The serum concentration of Quinine can be increased when it is combined with Tetracycline.]
[N05AE05, lurasidone, The therapeutic efficacy of Quinine can be decreased when used in combination with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Quinine.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Quinine.]
[L04AX02, thalidomide, Quinine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The serum concentration of Theobromine can be increased when it is combined with Quinine.]
[R03DA04, theophylline, The serum concentration of Theophylline can be increased when it is combined with Quinine.]
[P02CA02, thiabendazole, The metabolism of Quinine can be decreased when combined with Thiabendazole.]
[A11DA01, thiamine, The risk or severity of adverse effects can be increased when Quinine is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Quinine.]
[R06AD03, thiethylperazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Thiethylperazine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Quinine.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Quinine.]
[N05AB08, thioproperazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Quinine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Quinine.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Quinine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Quinine is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Quinine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Quinine is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Quinine.]
[S01AA12, tobramycin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Tobramycin.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Tolazamide.]
[M02AX02, tolazoline, Quinine may increase the hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Tolbutamide.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Quinine is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Quinine.]
[N06AF04, tranylcypromine, The metabolism of Quinine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Quinine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Quinine.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Quinine.]
[C03DB02, triamterene, The metabolism of Quinine can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Quinine is combined with Triazolam.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Trichlormethiazide.]
[A03AB12, mepenzolate, Quinine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Quinine is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Triflupromazine.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Quinine.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Quinine.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Quinine.]
[N04AA01, trihexyphenidyl, Quinine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Quinine.]
[A03AA05, trimebutine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01ED04, metipranolol, Quinine may increase the hypotensive activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Quinine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Quinine is combined with Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Quinine can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Quinine.]
[R06AC04, tripelennamine, The metabolism of Quinine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Quinine.]
[A03BB01, butylscopolamine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The serum concentration of Quinine can be increased when it is combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Quinine.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Quinine.]
[C09CA09, azilsartan medoxomil, Quinine may increase the hypotensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be increased when used in combination with Quinine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Quinine.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Quinine.]
[L02BX03, abiraterone, The serum concentration of Quinine can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Quinine is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Quinine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Quinine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Quinine.]
[B01AD04, urokinase, The therapeutic efficacy of Urokinase can be increased when used in combination with Quinine.]
[S01AA28, vancomycin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Vancomycin.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Quinine.]
[B01AF01, rivaroxaban, The therapeutic efficacy of Rivaroxaban can be increased when used in combination with Quinine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Quinine.]
[B01AC24, ticagrelor, The therapeutic efficacy of Ticagrelor can be increased when used in combination with Quinine.]
[C08DA01, verapamil, Verapamil may increase the hypotensive activities of Quinine.]
[N06AX09, viloxazine, The metabolism of Quinine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Quinine.]
[C04AX07, vincamine, Quinine may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Quinine.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Quinine.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Quinine.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Quinine.]
[C03BA10, xipamide, The therapeutic efficacy of Quinine can be increased when used in combination with Xipamide.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Quinine can be increased when used in combination with Pipemidic acid.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Quinine.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Quinine.]
[J05AE02, indinavir, The metabolism of Quinine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Quinine is combined with Levetiracetam.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quinine.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Quinine.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Quinine.]
[B01AE01, desirudin, The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine.]
[R03DC01, zafirlukast, The metabolism of Quinine can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Quinine.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Quinine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Quinine is combined with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Quinine can be decreased when used in combination with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Quinine.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Quinine.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Quinine.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Quinine.]
[L03AB11, peginterferon alfa-2a, The metabolism of Quinine can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Quinine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be increased when used in combination with Quinine.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Quinine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Quinine.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Quinine.]
[R07AX02, ivacaftor, The serum concentration of Quinine can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Quinine.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Quinine.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Quinine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Quinine.]
[M03BX01, baclofen, The therapeutic efficacy of Quinine can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Quinine.]
[G04BD12, mirabegron, The serum concentration of Quinine can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Quinine.]
[V03AX03, cobicistat, The metabolism of Quinine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Quinine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Quinine can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Quinine.]
[L04AA31, teriflunomide, The serum concentration of Quinine can be decreased when it is combined with Teriflunomide.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AX01, defibrotide, The therapeutic efficacy of Defibrotide can be increased when used in combination with Quinine.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Quinine.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Quinine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Quinine is combined with Barbital.]
[C01AA01, acetyldigitoxin, The serum concentration of Acetyldigitoxin can be increased when it is combined with Quinine.]
[J05AE04, nelfinavir, The metabolism of Quinine can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Quinine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Quinine.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Quinine is combined with Rasagiline.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Quinine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Quinine is combined with Mosapride.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Quinine.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Quinine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Quinine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Quinine.]
[R06AC06, thonzylamine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Quinine.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Quinine is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Quinine can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The therapeutic efficacy of Quinine can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Quinine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Quinine.]
[B01AF02, apixaban, The therapeutic efficacy of Apixaban can be increased when used in combination with Quinine.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Quinine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Quinine.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Quinine.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Quinine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Quinine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Quinine.]
[G03XC05, ospemifene, The metabolism of Quinine can be decreased when combined with Ospemifene.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Quinine is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Quinine.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Quinine.]
[M04AB03, benzbromarone, The metabolism of Quinine can be decreased when combined with Benzbromarone.]
[A12CC09, magnesium orotate, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium orotate.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quinine.]
[A06AX06, tegaserod, The metabolism of Tegaserod can be decreased when combined with Quinine.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Quinine.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Quinine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Pramlintide.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Quinine.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Quinine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Quinine is combined with Naratriptan.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Quinine.]
[A12CC05, magnesium aspartate, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium aspartate.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Quinine.]
[L01EC02, dabrafenib, The serum concentration of Quinine can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Quinine can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Quinine.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Quinine.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Quinine.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Quinine.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Quinine.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Quinine.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Lixisenatide.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Quinine.]
[C02KX04, macitentan, Quinine may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Quinine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Quinine.]
[G03AC08, etonogestrel, The therapeutic efficacy of Quinine can be decreased when used in combination with Etonogestrel.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Quinine is combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Quinine can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Quinine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Quinine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Quinine is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Quinine.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Quinine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Quinine is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Quinine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Quinine can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Quinine.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Quinine.]
[B01AE03, argatroban, The therapeutic efficacy of Argatroban can be increased when used in combination with Quinine.]
[C02CC01, bethanidine, Quinine may increase the hypotensive activities of Bethanidine.]
[C10AB02, bezafibrate, The metabolism of Quinine can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Quinine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Quinine.]
[B01AC26, vorapaxar, The therapeutic efficacy of Vorapaxar can be increased when used in combination with Quinine.]
[A03BA03, hyoscyamine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Quinine.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Quinine.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Quinine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Quinine is combined with Alfaxalone.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypoglycemic activities of Quinine.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Quinine.]
[S01EE02, unoprostone, Quinine may increase the hypotensive activities of Unoprostone.]
[D11AA01, glycopyrronium, Quinine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Quinine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Quinine.]
[J01XA05, oritavancin, The metabolism of Quinine can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Dihydrostreptomycin.]
[N05AA04, acepromazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Acepromazine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Dulaglutide.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Quinine.]
[N04AA02, biperiden, Quinine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Quinine.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Quinine.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Quinine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Quinine.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Quinine.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Quinine.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Quinine.]
[N06AX11, mirtazapine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Quinine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Quinine.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Quinine.]
[L01XH03, panobinostat, The metabolism of Quinine can be decreased when combined with Panobinostat.]
[J05AP07, daclatasvir, The serum concentration of Quinine can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Quinine.]
[A03AA09, difemerine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Quinine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Quinine.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Quinine.]
[B01AC25, cangrelor, The therapeutic efficacy of Cangrelor can be increased when used in combination with Quinine.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Quinine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Quinine.]
[A04AD14, rolapitant, The metabolism of Quinine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Quinine is combined with Flibanserin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Quinine is combined with Cariprazine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Quinine.]
[S01EC01, acetazolamide, The excretion of Quinine can be decreased when combined with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Quinine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Quinine.]
[J02AC05, isavuconazole, The serum concentration of Quinine can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Quinine can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Quinine.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Quinine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Quinine.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Quinine.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Quinine.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Acetohexamide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Quinine.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Quinine.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Quinine.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Quinine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Quinine is combined with Aprobarbital.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Quinine.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Quinine is combined with Brivaracetam.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Quinine.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium Aluminum Silicate.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Quinine is combined with Alverine.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Quinine.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Quinine.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Quinine.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Quinine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Quinine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Quinine is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Quinine can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, The therapeutic efficacy of Quinine can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Quinine.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Quinine.]
[N07BC01, buprenorphine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The therapeutic efficacy of Quinine can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, The metabolism of Buspirone can be decreased when combined with Quinine.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Quinine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Quinine is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Quinine is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Quinine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Quinine is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Quinine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Quinine.]
[S01GX07, azelastine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Quinine.]
[S01AA26, azithromycin, The serum concentration of Quinine can be increased when it is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Quinine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Quinine.]
[R03DA08, bamifylline, The serum concentration of Bamifylline can be increased when it is combined with Quinine.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Quinine.]
[N02BF02, pregabalin, The therapeutic efficacy of Quinine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Quinine is combined with Beclamide.]
[N06BC01, caffeine, The serum concentration of Caffeine can be increased when it is combined with Quinine.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Quinine.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Quinine is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Oxybuprocaine.]
[J01XX08, linezolid, Linezolid may increase the hypoglycemic activities of Quinine.]
[J05AE09, tipranavir, The risk or severity of torsade de pointes and Cardiac Arrhythmia can be increased when Tipranavir is combined with Quinine.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Quinine.]
[L04AB02, infliximab, The metabolism of Quinine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Quinine can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Quinine.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Quinine is combined with Safinamide.]
[J01MA23, delafloxacin, The therapeutic efficacy of Quinine can be increased when used in combination with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Quinine.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Quinine is combined with Acetylcholine.]
[L01BC06, capecitabine, The metabolism of Quinine can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Quinine.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Quinine.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Quinine.]
[L01XH01, vorinostat, The therapeutic efficacy of Quinine can be decreased when used in combination with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Quinine.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Quinine.]
[C07AB07, bisoprolol, The therapeutic efficacy of Quinine can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Quinine can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Quinine.]
[N04AA11, bornaprine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Quinine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Quinine is combined with Brotizolam.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Quinine.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Quinine.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Quinine is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Quinine.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Quinine.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Quinine.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Semaglutide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Quinine can be increased when used in combination with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Quinine is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Quinine.]
[C09AA01, captopril, Quinine may increase the hypotensive activities of Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Quinine is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Quinine can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Quinine.]
[A03AA03, camylofine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Quinine.]
[L03AB06, interferon alfa-n1, The metabolism of Quinine can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Quinine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Quinine.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Quinine.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Quinine.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Quinine.]
[J01GB14, plazomicin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Plazomicin.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Quinine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Quinine.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Quinine is combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Quinine.]
[N03AX17, stiripentol, The metabolism of Quinine can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Quinine.]
[J05AX24, tecovirimat, The metabolism of Quinine can be decreased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Quinine.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Quinine.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Quinine.]
[J01AA14, sarecycline, The serum concentration of Quinine can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Quinine.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Quinine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Quinine is combined with Carbromal.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Quinine.]
[R03DA02, oxtriphylline, The serum concentration of Oxtriphylline can be increased when it is combined with Quinine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Quinine.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Quinine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Quinine.]
[R03BB08, revefenacin, Quinine may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Quinine.]
[L04AA39, emapalumab, The metabolism of Quinine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Quinine can be decreased when combined with Carmustine.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Quinine.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Quinine.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Quinine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Quinine is combined with Amifampridine.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Quinine.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Quinine.]
[C09AA08, cilazapril, Quinine may increase the hypotensive activities of Cilazapril.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Quinine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Quinine is combined with Cinitapride.]
[S01ED05, carteolol, Quinine may increase the hypotensive activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Quinine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Quinine is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Quinine.]
[J01FA09, clarithromycin, The serum concentration of Quinine can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Quinine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Quinine is combined with Brexanolone.]
[L01EN01, erdafitinib, The serum concentration of Quinine can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Quinine can be decreased when combined with Clobazam.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Quinine.]
[J01AA11, clomocycline, The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Quinine.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Quinine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Quinine is combined with Cloxazolam.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Quinine.]
[C09CA06, candesartan, The metabolism of Quinine can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Quinine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Quinine.]
[L01EM03, alpelisib, The serum concentration of Quinine can be decreased when it is combined with Alpelisib.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Quinine.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Quinine.]
[N05AA06, cyamemazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Cyamemazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Quinine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Quinine.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Quinine.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Quinine.]
[N07XX11, pitolisant, The serum concentration of Quinine can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Quinine.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Quinine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Quinine.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Quinine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin pork.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Quinine.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Quinine.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Quinine.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Quinine.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Quinine.]
[N02CC08, lasmiditan, The serum concentration of Quinine can be increased when it is combined with Lasmiditan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Quinine.]
[G03AC09, desogestrel, The therapeutic efficacy of Quinine can be decreased when used in combination with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Quinine.]
[N03AX25, cenobamate, The serum concentration of Quinine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Quinine can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Quinine.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Quinine.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Quinine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Quinine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Quinine is combined with Dezocine.]
[L01EX18, avapritinib, The metabolism of Quinine can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Quinine.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Quinine.]
[L04AA53, teprotumumab, The therapeutic efficacy of Quinine can be decreased when used in combination with Teprotumumab.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Quinine.]
[M01AX21, diacetylrhein, The metabolism of Quinine can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Quinine.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Quinine can be increased when used in combination with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Quinine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Quinine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Quinine is combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Quinine.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Quinine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Quinine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Quinine.]
[G03DB08, dienogest, The therapeutic efficacy of Quinine can be decreased when used in combination with Dienogest.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Quinine is combined with Difenoxin.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Quinine.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Quinine.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Quinine.]
[M01AH02, rofecoxib, The metabolism of Quinine can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Quinine can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Quinine.]
[C01BD07, dronedarone, Quinine may increase the QTc-prolonging activities of Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Quinine is combined with Valpromide.]
[J01FA13, dirithromycin, The serum concentration of Quinine can be increased when it is combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Quinine can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Quinine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Quinine is combined with Chlordiazepoxide.]
[C02AA06, methoserpidine, Quinine may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Quinine which could result in a higher serum level.]
[A03AA08, dihexyverine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Quinine.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Quinine.]
[G04BD09, trospium, Quinine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Quinine.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Quinine.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Quinine.]
[B01AE02, lepirudin, The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Quinine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Quinine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Dyclonine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Quinine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Quinine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Quinine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Quinine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Quinine is combined with Remimazolam.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Quinine.]
[L04AC19, satralizumab, The serum concentration of Quinine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Quinine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Quinine.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Quinine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Quinine.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Quinine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Quinine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Quinine can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Quinine.]
[A11CC05, cholecalciferol, The metabolism of Quinine can be decreased when combined with Cholecalciferol.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Quinine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Quinine is combined with Etifoxine.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Quinine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Quinine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Quinine is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Quinine.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Quinine.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Quinine.]
[A16AX20, lonafarnib, The metabolism of Quinine can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Quinine.]
[L04AD03, voclosporin, The serum concentration of Voclosporin can be increased when it is combined with Quinine.]
[P03AX07, abametapir, The serum concentration of Quinine can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Quinine.]
[L01EX25, umbralisib, The serum concentration of Quinine can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Quinine.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Quinine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Quinine.]
[N06BA10, fenethylline, The serum concentration of Fenethylline can be increased when it is combined with Quinine.]
[C01CA19, fenoldopam, Quinine may increase the hypotensive activities of Fenoldopam.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Quinine.]
[J01MB07, flumequine, The therapeutic efficacy of Quinine can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Quinine.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Quinine.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Quinine.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Quinine.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Quinine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Quinine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Quinine can be increased when it is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Quinine may increase the hypotensive activities of Dasiglucagon.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Quinine.]
[A02BA01, cimetidine, The metabolism of Quinine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Quinine is combined with Gabapentin.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Quinine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Quinine.]
[L01XX73, sotorasib, The serum concentration of Quinine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Quinine.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Quinine.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Quinine.]
[N06AB04, citalopram, Quinine may increase the QTc-prolonging activities of Citalopram.]
[H01AC07, somapacitan, The therapeutic efficacy of Quinine can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Quinine.]
[L04AA48, belumosudil, The serum concentration of Quinine can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Quinine is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Quinine.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Quinine can be decreased when used in combination with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Quinine is combined with Mobocertinib.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Quinine.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Quinine.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Quinine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Quinine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Quinine.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Quinine is combined with Gliquidone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Quinine.]
[N06AX25, St. John's wort extract, The metabolism of Quinine can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Quinine can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Quinine can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Quinine.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Quinine.]
[D11AH08, abrocitinib, The serum concentration of Quinine can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Quinine.]
[B01AD11, tenecteplase, The therapeutic efficacy of Tenecteplase can be increased when used in combination with Quinine.]
[B06AX04, mitapivat, The serum concentration of Quinine can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Quinine can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Quinine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Quinine.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Quinine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Quinine.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Quinine.]
[C01EB24, mavacamten, The serum concentration of Quinine can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Quinine can be increased when used in combination with Clopamide.]
[A02BC08, vonoprazan, The metabolism of Quinine can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Quinine is combined with Clothiapine.]
[H01CC04, linzagolix, The serum concentration of Quinine can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Clotiazepam.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Quinine.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Quinine.]
[N05AH02, clozapine, The metabolism of Quinine can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Quinine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Quinine is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Quinine is combined with Sotagliflozin.]
[J01GB12, arbekacin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Arbekacin.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Halazepam.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Quinine.]
[H01AC08, somatrogon, The therapeutic efficacy of Quinine can be decreased when used in combination with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Cocaine.]
[C02KB01, metyrosine, Quinine may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Quinine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Quinine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Quinine is combined with Hexafluronium.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Quinine.]
[A03AB10, hexocyclium, Quinine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Quinine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Colistin.]
[L04AA13, leflunomide, The serum concentration of Quinine can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Quinine.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Quinine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Quinine is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Quinine.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Quinine is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin glargine.]
[J01FA15, telithromycin, The serum concentration of Quinine can be increased when it is combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Quinine.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Quinine.]
[M01AH03, valdecoxib, The metabolism of Quinine can be decreased when combined with Valdecoxib.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Quinine.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Quinine.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Isometheptene.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Quinine.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Quinine.]
[J02AC02, itraconazole, The metabolism of Quinine can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The therapeutic efficacy of Bemiparin can be increased when used in combination with Quinine.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Quinine.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Quinine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Quinine is combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Quinine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Quinine can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Quinine can be decreased when combined with Esomeprazole.]
[S01EE04, travoprost, Quinine may increase the hypotensive activities of Travoprost.]
[S01EE03, bimatoprost, Quinine may increase the hypotensive activities of Bimatoprost.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Quinine.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Quinine.]
[N03AX09, lamotrigine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Quinine.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Quinine.]
[N07BC04, lofexidine, The therapeutic efficacy of Quinine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Quinine.]
[R06AX13, loratadine, The metabolism of Quinine can be decreased when combined with Loratadine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Lormetazepam.]
[C09AA03, lisinopril, Quinine may increase the hypotensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B05XA10, magnesium phosphate, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium phosphate.]
[C08CA11, manidipine, The metabolism of Quinine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Quinine is combined with Medifoxamine.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Quinine.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Quinine.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Quinine.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Quinine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Quinine.]
[N04AA03, methixene, Quinine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Quinine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Quinine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Quinine is combined with Cyclobarbital.]
[C03DA04, eplerenone, Quinine may increase the hypotensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Quinine.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Cyclopenthiazide.]
[J01FA03, midecamycin, The serum concentration of Quinine can be increased when it is combined with Midecamycin.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Quinine is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Quinine.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Quinine.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Quinine.]
[S01XA18, cyclosporine, The metabolism of Quinine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be decreased when combined with Quinine.]
[N06BA07, modafinil, The metabolism of Quinine can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Quinine.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Quinine can be increased when used in combination with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Quinine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Quinine may increase the hypotensive activities of Moxonidine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Quinine is combined with Cytarabine.]
[J05AF10, entecavir, The metabolism of Quinine can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Quinine.]
[M01AH05, etoricoxib, The metabolism of Quinine can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Quinine.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Quinine.]
[G03XA01, danazol, The metabolism of Quinine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Quinine is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Quinine.]
[L01DB02, daunorubicin, The metabolism of Quinine can be increased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Quinine is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Quinine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Quinine.]
[M01AX01, nabumetone, The metabolism of Quinine can be decreased when combined with Nabumetone.]
[J01AA01, demeclocycline, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Demeclocycline.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Quinine.]
[N06AX06, nefazodone, The metabolism of Quinine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Quinine is combined with Niaprazine.]
[C01DX16, nicorandil, Quinine may increase the hypotensive activities of Nicorandil.]
[L02BB02, nilutamide, The metabolism of Quinine can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Quinine is combined with Tiagabine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Quinine.]
[C01CA23, theodrenaline, The serum concentration of Theodrenaline can be increased when it is combined with Quinine.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Quinine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Quinine is combined with Normethadone.]
[B01AX05, fondaparinux, The therapeutic efficacy of Fondaparinux can be increased when used in combination with Quinine.]
[N06AB10, escitalopram, The serum concentration of Quinine can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Quinine.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Quinine.]
[N06AA01, desipramine, The metabolism of Desipramine can be decreased when combined with Quinine.]
[C01AA07, deslanoside, The serum concentration of Deslanoside can be increased when it is combined with Quinine.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Quinine.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Quinine.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Quinine.]
[C09XA02, aliskiren, Quinine may increase the hypotensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quinine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Quinine is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Quinine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Quinine is combined with Oxiracetam.]
[N04AA08, dexetimide, Quinine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Quinine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Quinine.]
[A03AA01, oxyphencyclimine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Quinine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Quinine.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Quinine.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Quinine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Quinine is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Quinine is combined with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Quinine.]
[B01AC04, clopidogrel, The metabolism of Quinine can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Quinine is combined with Diamorphine.]
[C04AD01, pentifylline, The serum concentration of Pentifylline can be increased when it is combined with Quinine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Quinine is combined with Phenacemide.]
[V03AH01, diazoxide, The therapeutic efficacy of Quinine can be decreased when used in combination with Diazoxide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Quinine is combined with Phensuximide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Quinine.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Cinchocaine.]
[S01EC02, dichlorphenamide, The excretion of Quinine can be decreased when combined with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Quinine.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Quinine.]
[A03AA07, dicyclomine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Quinine can be increased when used in combination with Phthalylsulfathiazole.]
[C02DG01, pinacidil, Quinine may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Quinine.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Quinine is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Quinine is combined with Pipamperone.]
[A03AB14, pipenzolate, Quinine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The serum concentration of Quinine can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Quinine.]
[C03CA03, piretanide, The therapeutic efficacy of Quinine can be increased when used in combination with Piretanide.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Quinine is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Quinine.]
[C08CA03, isradipine, The metabolism of Quinine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Quinine.]
[A03AB11, poldine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Quinine.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Quinine.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Quinine.]
[C02DB01, dihydralazine, The metabolism of Quinine can be decreased when combined with Dihydralazine.]
[C10AX09, ezetimibe, The excretion of Ezetimibe can be decreased when combined with Quinine.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Quinine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Quinine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Quinine.]
[J05AE08, atazanavir, The metabolism of Quinine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Quinine.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Pramocaine.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Quinine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Quinine.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Quinine.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Quinine is combined with Pridinol.]
[R06AB03, dimethindene, Quinine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Quinine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Quinine is combined with Progabide.]
[N06BC02, propentofylline, The serum concentration of Propentofylline can be increased when it is combined with Quinine.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Quinine.]
[C05CA03, diosmin, The serum concentration of Quinine can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Proparacaine.]
[R03DA03, proxyphylline, The serum concentration of Proxyphylline can be increased when it is combined with Quinine.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Quinine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Quinine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Quazepam.]
[C09AA06, quinapril, Quinine may increase the hypotensive activities of Quinapril.]
[B01AC07, dipyridamole, The therapeutic efficacy of Dipyridamole can be increased when used in combination with Quinine.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Quinine is combined with Dexmethylphenidate.]
[B01AD10, drotrecogin alfa, The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinine.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Quinine.]
[A03FA02, cisapride, The metabolism of Quinine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Quinine may increase the hypotensive activities of Ramipril.]
[S01XA23, sirolimus, The serum concentration of Quinine can be increased when it is combined with Sirolimus.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Quinine.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Quinine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Quinine.]
[S02AA12, rifamycin SV, The metabolism of Quinine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Quinine can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Quinine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Quinine is combined with Riluzole.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Quinine.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Quinine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Ropivacaine.]
[J01MB01, rosoxacin, The therapeutic efficacy of Quinine can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Quinine.]
[A04AD12, aprepitant, The metabolism of Quinine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Quinine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Quinine.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Quinine can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Quinine may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Quinine.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Quinine.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Quinine.]
[R03AC12, salmeterol, The metabolism of Quinine can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Quinine.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Quinine.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Quinine.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Quinine.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Quinine.]
[J01AA02, doxycycline, The risk or severity of neuromuscular blockade can be increased when Doxycycline is combined with Quinine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quinine.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Quinine.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Quinine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Quinine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Quinine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Quinine.]
[C09AA11, spirapril, Quinine may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, The serum concentration of Dyphylline can be increased when it is combined with Quinine.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Quinine can be increased when used in combination with Succinylsulfathiazole.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Quinine.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Quinine is combined with Sumatriptan.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Quinine.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Quinine.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Quinine is combined with Temafloxacin.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Quinine.]
[G04CA03, terazosin, Quinine may increase the hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Quinine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Quinine is combined with Terodiline.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Quinine.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Quinine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Quinine is combined with Thiopropazate.]
[G04BD01, emepronium, Quinine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Quinine.]
[C09AA02, enalapril, Quinine may increase the hypotensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Quinine is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Quinine is combined with Toloxatone.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Quinine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Quinine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Quinine is combined with Toremifene.]
[C03CA04, torsemide, The therapeutic efficacy of Quinine can be decreased when used in combination with Torasemide.]
[J01AA12, tigecycline, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Tigecycline.]
[C09AA10, trandolapril, Quinine may increase the hypotensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Quinine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Quinine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Quinine is combined with Triclofos.]
[A03AB08, tridihexethyl, Quinine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The therapeutic efficacy of Triflusal can be increased when used in combination with Quinine.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Quinine.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Quinine is combined with Trimethobenzamide.]
[L02AE04, triptorelin, The therapeutic efficacy of Quinine can be decreased when used in combination with Triptorelin.]
[N04AA12, tropatepine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The therapeutic efficacy of Troxerutin can be increased when used in combination with Quinine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Quinine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Quinine is combined with Urapidil.]
[J01MA04, enoxacin, The metabolism of Quinine can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Quinine is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Quinine.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Quinine.]
[N06AX16, venlafaxine, The metabolism of Quinine can be decreased when combined with Venlafaxine.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Quinine.]
[C08CA12, mepirodipine, The metabolism of Quinine can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Quinine can be decreased when used in combination with Epinephrine.]
[C09AA15, zofenopril, Quinine may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Quinine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The excretion of Quinine can be decreased when combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Quinine.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Quinine is combined with Zotepine.]
[B01AD03, anistreplase, The therapeutic efficacy of Anistreplase can be increased when used in combination with Quinine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Quinine is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Quinine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Quinine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Quinine can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Quinine.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Quinine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Quinine is combined with Estazolam.]
[A02BC02, pantoprazole, The metabolism of Quinine can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Quinine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The therapeutic efficacy of Quinine can be decreased when used in combination with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Quinine can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Quinine can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Quinine.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Quinine.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Quinine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quinine.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Quinine.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Quinine can be decreased when used in combination with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Quinine.]
[N04AA05, profenamine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Quinine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Quinine is combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Quinine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Quinine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Quinine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Quinine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Quinine.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Quinine.]
[J01MA08, fleroxacin, The therapeutic efficacy of Quinine can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Quinine.]
[R06AX12, terfenadine, The metabolism of Quinine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Quinine.]
[N06AB08, fluvoxamine, The metabolism of Quinine can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Quinine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Quinine.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinine.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Quinine.]
[B05AA05, dextran, The therapeutic efficacy of Dextran can be increased when used in combination with Quinine.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Quinine.]
[P02CA03, albendazole, The metabolism of Quinine can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Quinine can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Quinine.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Quinine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Quinine.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Quinine.]
[B01AD05, plasmin, The therapeutic efficacy of Fibrinolysin can be increased when used in combination with Quinine.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Quinine.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Quinine.]
[G04BD02, flavoxate, Quinine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Quinine.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Quinine is combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Quinine.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Quinine.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Quinine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Quinine.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Quinine.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Quinine.]
[V03AZ01, ethanol, Quinine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Quinine can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Quinine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Quinine.]
[N06AB03, fluoxetine, The serum concentration of Quinine can be increased when it is combined with Fluoxetine.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Quinine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Quinine is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Fluphenazine.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Quinine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Flurazepam.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Quinine.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Quinine.]
[L02BB01, flutamide, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Flutamide.]
[S01AA07, framycetin, The risk or severity of neuromuscular blockade can be increased when Framycetin is combined with Quinine.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Quinine.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be increased when used in combination with Quinine.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Quinine is combined with Furazolidone.]
[J05AE10, darunavir, The metabolism of Quinine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Quinine can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Quinine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Quinine.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Quinine.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be increased when used in combination with Quinine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Quinine.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Quinine is combined with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Quinine is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Quinine is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Quinine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Quinine.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Quinine.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Quinine.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Quinine.]
[C01CA21, cafedrine, The serum concentration of Cafedrine can be increased when it is combined with Quinine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Quinine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Quinine.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Quinine.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Quinine is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Quinine.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Quinine is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Quinine is combined with Glutethimide.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Quinine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Quinine.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Quinine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Quinine.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Quinine.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Quinine.]
[C09AA09, fosinopril, Quinine may increase the hypotensive activities of Fosinopril.]
[S01EX01, guanethidine, Quinine may increase the hypotensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinine.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation, ventricular arrhythmias, torsade de pointes, and convulsion can be increased when Quinine is combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Quinine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Quinine is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Quinine is combined with Halothane.]
[L02AE05, histrelin, The therapeutic efficacy of Quinine can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Quinine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Quinine is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Quinine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Quinine is combined with Allobarbital.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Quinine.]
[S01XA14, heparin, The therapeutic efficacy of Heparin can be increased when used in combination with Quinine.]
[B05CB03, magnesium citrate, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium citrate.]
[A12CC03, magnesium gluconate, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium gluconate.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Quinine.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Quinine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Quinine is combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Quinine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Quinine.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Quinine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Quinine.]
[C09AA04, perindopril, Quinine may increase the hypotensive activities of Perindopril.]
[C02DB02, hydralazine, Quinine may increase the hypotensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Quinine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Quinine.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Quinine.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Quinine.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Quinine.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Hydroflumethiazide.]
[G04BD06, propiverine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Quinine can be increased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Quinine is combined with Prothipendyl.]
[L01XX05, hydroxyurea, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Quinine can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Quinine may increase the hypotensive activities of Rilmenidine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Quinine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Quinine.]
[B05CB02, sodium citrate, The therapeutic efficacy of Sodium citrate can be increased when used in combination with Quinine.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Quinine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Quinine.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Quinine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Quinine is combined with Sufentanil.]
[N06AA02, imipramine, The metabolism of Quinine can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Quinine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Quinine.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Quinine.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Quinine.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Quinine.]
[C03BA11, indapamide, The therapeutic efficacy of Quinine can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Quinine.]
[C02CA02, indoramin, Quinine may increase the hypotensive activities of Indoramin.]
[L03AB04, interferon alfa-2a, The metabolism of Quinine can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Quinine can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Quinine.]
[A03AA30, piperidolate, Quinine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Quinine is combined with Cyclopentamine.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Quinine.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Quinine is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Quinine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Quinine is combined with Ramelteon.]
[R06AE01, buclizine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Quinine is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Quinine.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Quinine.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be decreased when combined with Quinine.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinine can be decreased when used in combination with Quinethazone.]
[L03AB09, interferon alfacon-1, The metabolism of Quinine can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Quinine.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Quinine.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Quinine is combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Quinine can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Quinine is combined with Isocarboxazid.]
[S01EC03, dorzolamide, Quinine may increase the hypotensive activities of Dorzolamide.]
[P01AX06, atovaquone, The metabolism of Quinine can be decreased when combined with Atovaquone.]
[C09AA16, imidapril, Quinine may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Quinine.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Quinine is combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Quinine can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Isosorbide dinitrate.]
[B01AE06, bivalirudin, The therapeutic efficacy of Bivalirudin can be increased when used in combination with Quinine.]
[J01FA07, josamycin, The serum concentration of Quinine can be increased when it is combined with Josamycin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Quinine.]
[S01AA24, kanamycin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Kanamycin.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Quinine.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The metabolism of Quinine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Quinine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Quinine is combined with Ketanserin.]
[B01AC22, prasugrel, The therapeutic efficacy of Prasugrel can be increased when used in combination with Quinine.]
[H02CA04, levoketoconazole, The metabolism of Quinine can be decreased when combined with Levoketoconazole.]
[J02AB02, ketoconazole, The metabolism of Quinine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be decreased when combined with Quinine.]
[M02AA10, ketoprofen, The metabolism of Quinine can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Quinine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Quinine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Quinine.]
[N04BC09, rotigotine, Quinine may increase the sedative activities of Rotigotine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Quinine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Quinine.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Quinine.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Quinine.]
[C02AA05, deserpidine, Quinine may increase the hypotensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Quinine is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Quinine can be decreased when used in combination with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Quinine can be decreased when used in combination with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Quinine is combined with Levodopa.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Quinine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Quinine.]
[J01FF02, lincomycin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Lincomycin.]
[N06BA13, armodafinil, The metabolism of Quinine can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Quinine.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Quinine.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Quinine.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Quinine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Quinine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Quinine.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Quinine.]
[J01AA04, lymecycline, The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Quinine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Quinine.]
[L01EG01, temsirolimus, The serum concentration of Quinine can be increased when it is combined with Temsirolimus.]
[B05XA11, magnesium chloride, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Magnesium chloride.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Quinine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Quinine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Quinine.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Quinine.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Quinine is combined with Mazindol.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Quinine is combined with Mecamylamine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Quinine.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Medazepam.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Quinine.]
[P01BC02, mefloquine, The risk or severity of adverse effects can be increased when Quinine is combined with Mefloquine.]
[C03BA05, mefruside, The therapeutic efficacy of Quinine can be increased when used in combination with Mefruside.]
[B01AB06, nadroparin, The therapeutic efficacy of Nadroparin can be increased when used in combination with Quinine.]
[B01AB05, enoxaparin, The therapeutic efficacy of Enoxaparin can be increased when used in combination with Quinine.]
[B01AB04, dalteparin, The therapeutic efficacy of Dalteparin can be increased when used in combination with Quinine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Quinine is combined with Melatonin.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Quinine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Quinine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Quinine.]
[N03AA01, mephobarbital, The serum concentration of Methylphenobarbital can be increased when it is combined with Quinine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Quinine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Quinine is combined with Meptazinol.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Quinine.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Quinine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Quinine.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Quinine is combined with Metformin.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Quinine.]
[H01CB03, lanreotide, The therapeutic efficacy of Quinine can be decreased when used in combination with Lanreotide.]
[J01AA05, methacycline, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Metacycline.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Quinine.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Quinine.]
[A03AB07, methantheline, Quinine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Quinine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Quinine is combined with Methaqualone.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Quinine.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Quinine.]
[S01EC05, methazolamide, The excretion of Quinine can be decreased when combined with Methazolamide.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Quinine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Quinine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be decreased when combined with Quinine.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Quinine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Quinine is combined with Methohexital.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Quinine is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Quinine.]
[N05AA02, methotrimeprazine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Quinine can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Quinine.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Quinine may increase the hypotensive activities of Methyldopa.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Quinine.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be increased when it is combined with Quinine.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Quinine.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Quinine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Quinine.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Quinine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Quinine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Quinine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Quinine.]
[C03BA08, metolazone, The therapeutic efficacy of Quinine can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The metabolism of Quinine can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Quinine.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Quinine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Quinine.]
[S02AA13, miconazole, The metabolism of Quinine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Quinine.]
[B01AB07, parnaparin, The therapeutic efficacy of Parnaparin can be increased when used in combination with Quinine.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Quinine.]
[G03XB01, mifepristone, The serum concentration of Quinine can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The therapeutic efficacy of Tinzaparin can be increased when used in combination with Quinine.]
[C09CA03, valsartan, The metabolism of Quinine can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Quinine.]
[D11AX01, minoxidil, Quinine may increase the hypotensive activities of Minoxidil.]
[J01FA11, miocamycin, The serum concentration of Quinine can be increased when it is combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Quinine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Quinine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Quinine is combined with Molindone.]
[C01BD01, amiodarone, The metabolism of Quinine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Quinine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Quinine.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Quinine.]
[L04AB05, certolizumab pegol, The metabolism of Quinine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Quinine.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Quinine.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be increased when used in combination with Quinine.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Quinine is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Quinine.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Quinine.]
[R03BB01, ipratropium bromide, Quinine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G03XC01, raloxifene, The metabolism of Quinine can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Quinine.]
[N03AB05, fosphenytoin, The serum concentration of Quinine can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Quinine can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Quinine.]
[N04BC04, ropinirole, Quinine may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Quinine can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Quinine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Quinine is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Quinine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Quinine.]
[L04AC03, anakinra, The metabolism of Quinine can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Quinine.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Quinine.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Quinine.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Quinine is combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be decreased when combined with Quinine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Quinine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Quinine.]
[L02BG04, letrozole, The metabolism of Quinine can be decreased when combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Neomycin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Quinine is combined with Remifentanil.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Quinine is combined with Repaglinide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Quinine.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Quinine.]
[S01AA23, netilmicin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Netilmicin.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Quinine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Quinine can be decreased when combined with Telmisartan.]
[C10AD02, niacin, The therapeutic efficacy of Quinine can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Quinine is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Quinine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Quinine.]
[P02DA01, niclosamide, The metabolism of Quinine can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Quinine is combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Quinine.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Quinine.]
[C08CA07, nisoldipine, The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Quinine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Quinine.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Nitric Oxide is combined with Quinine.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Nitrofurantoin.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Quinine is combined with Zaleplon.]
[N04BC05, pramipexole, Quinine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Nitroprusside is combined with Quinine.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Quinine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Quinine is combined with Nomifensine.]
[C01CA03, norepinephrine, The serum concentration of Norepinephrine can be increased when it is combined with Quinine.]
[G03DC02, norethindrone, The therapeutic efficacy of Quinine can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Quinine can be increased when used in combination with Norfloxacin.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Quinine.]
[C02KX01, bosentan, The therapeutic efficacy of Quinine can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Quinine.]
[R05DA07, noscapine, The metabolism of Quinine can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Quinine can be increased when it is combined with Sapropterin.]
[L03AB07, interferon beta-1a, The metabolism of Quinine can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Quinine.]
[B01AB08, reviparin, The therapeutic efficacy of Reviparin can be increased when used in combination with Quinine.]
[H01CB02, octreotide, The therapeutic efficacy of Quinine can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Quinine.]
[J01FA05, oleandomycin, The serum concentration of Quinine can be increased when it is combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Quinine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Quinine.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Quinine.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Quinine.]
[B01AD07, reteplase, The therapeutic efficacy of Reteplase can be increased when used in combination with Quinine.]
[B01AD09, ancrod, The therapeutic efficacy of Ancrod can be increased when used in combination with Quinine.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Quinine.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Quinine.]
[P02BA02, oxamniquine, The metabolism of Quinine can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Quinine can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Oxazepam.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Quinine can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The metabolism of Oxprenolol can be decreased when combined with Quinine.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Quinine.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Quinine.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Quinine.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Quinine is combined with Oxypertine.]
[A03AB03, oxyphenonium, Quinine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[S01AA04, oxytetracycline, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Oxytetracycline.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinine.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Quinine.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Asenapine.]
[B01AB09, danaparoid, The therapeutic efficacy of Danaparoid can be increased when used in combination with Quinine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Quinine.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be increased when used in combination with Quinine.]
[J04AB30, capreomycin, The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Quinine.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Quinine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quinine.]
[N05CC05, paraldehyde, Quinine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Quinine.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Quinine is combined with Pargyline.]
[A07AA06, paromomycin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Paromomycin.]
[J01MA03, pefloxacin, The therapeutic efficacy of Quinine can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Quinine.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be decreased when combined with Quinine.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Quinine.]
[M01CC01, penicillamine, The excretion of Penicillamine can be decreased when combined with Quinine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Quinine.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Quinine is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Quinine can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The serum concentration of Pentoxifylline can be increased when it is combined with Quinine.]
[N05AB10, perazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Quinine is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Quinine.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Quinine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Quinine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Quinine is combined with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Quinine is combined with Phenelzine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Quinine.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Quinine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Quinine.]
[N03AA02, phenobarbital, The serum concentration of Phenobarbital can be increased when it is combined with Quinine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Quinine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Quinine.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Quinine.]
[A08AA01, phentermine, The therapeutic efficacy of Quinine can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Quinine may increase the hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The metabolism of Quinine can be decreased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Quinine can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Quinine can be decreased when combined with Dexlansoprazole.]
[N03AB02, phenytoin, The serum concentration of Quinine can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Quinine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Quinine.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Quinine.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Quinine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Quinine.]
[C07AA03, pindolol, The metabolism of Pindolol can be decreased when combined with Quinine.]
[C10AA05, atorvastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Quinine is combined with Atorvastatin.]
[J01CA12, piperacillin, The risk or severity of neuromuscular blockade can be increased when Piperacillin is combined with Quinine.]
[J05AE01, saquinavir, The metabolism of Quinine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Quinine.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Quinine.]
[C09CA02, eprosartan, Quinine may increase the hypotensive activities of Eprosartan.]
[A02BX03, pirenzepine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Quinine is combined with Piritramide.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Quinine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Quinine.]
[N02CX01, pizotyline, Quinine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Quinine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Quinine.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Quinine is combined with Proxibarbal.]
[B01AC13, abciximab, The therapeutic efficacy of Abciximab can be increased when used in combination with Quinine.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Quinine.]
[S01XA13, alteplase, The therapeutic efficacy of Alteplase can be increased when used in combination with Quinine.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Quinine.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Quinine.]
[A03AE01, alosetron, The metabolism of Quinine can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Quinine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Quinine can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Quinine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Quinine is combined with Saxagliptin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Quinine.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Quinine.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Quinine.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Quinine is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Quinine.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Quinine.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Quinine.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Quinine.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Quinine.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Quinine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Quinine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Primidone can be increased when it is combined with Quinine.]
[M04AB01, probenecid, The therapeutic efficacy of Quinine can be increased when used in combination with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Quinine.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Quinine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Quinine is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Quinine.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Quinine.]
[N04AA04, procyclidine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Quinine.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Quinine.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Quinine.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Quinine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Quinine is combined with Propanidid.]
[A03AB05, propantheline, Quinine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Quinine.]
[N05AC01, periciazine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Periciazine.]
[N05CM06, propiomazine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Quinine.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Quinine.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Quinine.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Quinine.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Quinine.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Quinine is combined with Rizatriptan.]
[B01AC09, epoprostenol, The therapeutic efficacy of Epoprostenol can be increased when used in combination with Quinine.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Quinine.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Quinine.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Quinine can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Quinine.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Quinine is combined with Dalfampridine.]
[A03AB15, diphemanil, Quinine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Quinine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Quinine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Quinine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Quinine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Quinine is combined with Styramate.]
[P02CC01, pyrantel, The therapeutic efficacy of Pyrantel can be increased when used in combination with Quinine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Quinine.]
[P01BD01, pyrimethamine, The metabolism of Quinine can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Quinine.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Quinine.]
[N07XX04, sodium oxybate, Quinine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Quinine.]
[C02AA01, rescinnamine, Quinine may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Quinine.]
[J04AB02, rifampin, The metabolism of Quinine can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Quinine is combined with Oxitriptan.]
[J01AA09, rolitetracycline, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Rolitetracycline.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Quinine.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Quinine.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Quinine.]
[S01FA02, scopolamine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The metabolism of Quinine can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Quinine.]
[J01GB08, sisomicin, The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Sisomicin.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Quinine.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Quinine.]
[C03DA01, spironolactone, The metabolism of Quinine can be decreased when combined with Spironolactone.]
